The FIFARMA Patient W.A.I.T. Indicator 2025, developed by IQVIA, analyzes access to 403 innovative medicines in 10 Latin American countries, revealing that patients wait an average of over five and a half years to access treatments approved by the FDA and EMA. Only 61% of these medicines receive approval in the region, and just one-third make it to the public sector. The study aims to highlight these gaps and promote solutions to improve equity and timely access to innovative therapies.